Your gift is 100% tax deductible.
Other Drugs Used to Treat Thymus Tumors
Some drugs that are not standard chemotherapy drugs might also be used to treat thymus tumors. These are usually tried after chemotherapy has been used first.
Octreotide for thymus tumors
Octreotide (Sandostatin) is a lab-made version of a natural hormone called somatostatin. It can be given with a steroid medicine called prednisone. When octreotide binds to somatostatin receptors on cancer cells, it may help slow tumor growth.
Before treatment with this drug, doctors order a PET/CT scan to see if the tumor has octreotide or dotatate receptors. The imaging test shows the receptors and helps doctors predict whether the drug is likely to work.
Who is treated with octreotide?
Octreotide is typically considered for people with advanced or recurrent thymoma that hasn't responded to other treatments. Or it can be an option for people who aren't healthy enough for standard chemotherapy. It's used more often and tends to work better in thymoma than in thymic carcinoma. This is because thymic carcinoma cells are less likely to have somatostatin receptors.
How is octreotide given?
One version of octreotide is short-acting and is injected 2 to 4 times a day under the skin. There is also a long-acting form of the drug that only needs to be injected into a muscle every 4 weeks. This drug is called Sandostatin LAR Depot. Treatment is usually continued for as long as it helps control the cancer.
What are side effects of octreotide for thymus tumors?
Octreotide tends to cause fewer side effects than standard chemotherapy. However, side effects of this treatment can include:
- Nausea, diarrhea, or stomach cramping
- Gallstones with long-term use
- Changes in blood sugar levels (it can raise or lower blood sugar)
- Pain or irritation at the injection site
Because octreotide is often combined with prednisone, side effects from the steroid can also occur, such as:
- Increased appetite and weight gain
- Trouble sleeping
- Mood changes
- Increased blood sugar
- Higher risk of infection with long-term use
Most side effects are mild compared to those from standard chemotherapy. Tell your healthcare team about any side effects that you notice so they can help manage them.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS; Eastern Cooperative Oncology Group. Octreotide Alone or with Prednisone in Patients with Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22(2):293-299.
Lo Russo G, Pusceddu S, Prinzi N, et al. The Role of Somatostatin Analogues in the Treatment of Advanced Malignant Thymomas: Case Report and Review of the Literature. Anticancer Res. 2012;32(11):4979-4985.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Thymomas and Thymic Carcinomas. Version 2.2026. Accessed at https://www.nccn.org on Jun 10, 2026.
Palmieri G, Lastoria S, Colao A, et al. Successful Treatment of a Patient with a Thymoma and Pure Red-Cell Aplasia with Octreotide and Prednisone. N Engl J Med. 1997;336(4):263-265.
Roden AC, Rakshit S, Johnson GB, Jenkins SM, Mansfield AS. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan, and Octreotide Treatment in Thymic Epithelial Tumors. Front Oncol. 2022;12:823667.
Last Revised: August 12, 2026
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


